SanBio Company Limited
4592
Rank in Stocks
#13005
SanBio Company Limited is dedicated to the creation, production, and sale of... SanBio Company Limited is dedicated to the creation, production, and sale of regenerative cell therapies, primarily concentrated on disorders of the central nervous system. A central component of their portfolio is SB623, a treatment that has completed Phase 2 clinical trials in both the United States and Japan for traumatic brain injury. Beyond this, their comprehensive research pipeline explores the broader potential of SB623 for conditions such as ischemic and hemorrhagic strokes, age-related macular degeneration, retinitis pigmentosa, spinal cord injury, Parkinson's disease, and Alzheimer's disease. The company's development efforts also encompass other innovative treatments: SB618 for peripheral nerve damage, SB308 for muscular dystrophy, MSC1 for cancer, and MSC2 for inflammatory diseases and optic neuritis. Founded in 2001, SanBio maintains its corporate headquarters in Tokyo, Japan.
Share Price
$5.42
Last synced: 2026-11-10
Market Cap
$422.93M
Change (1 day)
3.13%
Change (1 year)
-67.92%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade SanBio Company Limited (4592)
Category
Healthcare
EPS for SanBio Company Limited (4592)
EPS as of July 2026 TTM: $-0.30
According to SanBio Company Limited's latest financial reports, its current EPS (TTM) is $-0.30. At the end of 2025 the company had an EPS of $-0.27, an increase over its 2024 EPS of $-0.28.
EPS history for SanBio Company Limited from 2014 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.30 | 11.89% |
| 2025 | $-0.27 | -2.14% |
| 2024 | $-0.28 | -62.64% |
| 2023 | $-0.74 | -5.98% |
| 2022 | $-0.78 | 25.64% |
| 2021 | $-0.62 | -32.94% |
| 2020 | $-0.93 | 68.50% |
| 2019 | $-0.55 | -30.50% |
| 2018 | $-0.80 | 119.18% |
| 2017 | $-0.36 | 94.11% |
| 2016 | $-0.19 | -149.60% |
| 2015 | $0.38 | -349.87% |
| 2014 | $-0.15 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -5,283.71% |
US
|
|
| $-7.07 | 2,240.28% |
US
|
|
| $-5.29 | 1,651.08% |
AU
|
|
| $12.88 | -4,363.52% |
BE
|
|
| $21.56 | -7,236.71% |
NL
|
Questions about SanBio Company Limited's earnings per share (EPS)
What is SanBio Company Limited's earnings per share (EPS)?
SanBio Company Limited's earnings per share (EPS) over the last twelve months is $-0.30, as of Jul 2026.
What was SanBio Company Limited's earnings per share (EPS) in 2025?
In 2025, SanBio Company Limited's earnings per share (EPS) was $-0.27, compared with $-0.28 in 2024.
How has SanBio Company Limited's earnings per share (EPS) changed since 2020?
From 2020 to 2025, SanBio Company Limited's earnings per share (EPS) was highest in 2025 ($-0.27) and lowest in 2020 ($-0.93).
How does SanBio Company Limited's earnings per share (EPS) compare with similar companies?
SanBio Company Limited's earnings per share (EPS) ($-0.30) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.